The computational and the above cell-based results strongly suggested that JT003 is an AdipoR1 and AdipoR2 agonist with great potential in ameliorating NASH and related fibrosis. This evidence concerns the gene ADIPOR2 and metabolic dysfunction-associated steatohepatitis.